Global Porcine Vaccine Market Size By Disease Indication (Swine Influenza, Diarrhea, Arthritis), By Technology (Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines), By Geographic Scope And Forecast

Porcine Vaccine Market Size And Forecast

Porcine Vaccine Market size was valued at USD 2.19 Billion in 2024 and is projected to reach USD 3.83 Billion by 2032, growing at a CAGR of 7.27% from 2026 to 2032.

Some of the key contributing factors propelling the growth of the Global Porcine Vaccine Market are an increase in pork consumption and a rise in the prevalence of swine diseases. Also, governments across the globe are spending higher in the field of animal health care. The Global Porcine Vaccine Market report provides a holistic evaluation of the market for the forecast period. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.

Global Porcine Vaccine Market Definition

Vaccines are the most important disease prevention tools for both animals and humans. Vaccination is regarded as a boon in veterinary pharmaceuticals for preserving animal welfare by avoiding the spread of many endemic diseases. Porcine vaccines are used clinically to improve swine health and protect them from deadly diseases by guarding them against viruses, bacteria, and other pathogens.

Such diseases include porcine reproductive and respiratory virus (PRRSV), swine influenza, and porcine circovirus-associated disease (PCVAD) among others. It also increases the yield of high-quality meat for human consumption while improving overall efficiency in protecting pigs from deadly viruses. In North America and Europe, many diseases like cholera, foot & mouth disease have been significantly eliminated by using these vaccines.

Global Porcine Vaccine Market Overview

The increase in pork consumption is an important driver for the Global Porcine Vaccine Market. This increase in consumption is expected to result in a greater need to keep the swine population free of any disease that could affect them and pose a threat to humans. Thus the demand for swine vaccines that guards against various porcine diseases is expected to rise.

Also, higher instances of swine flu, porcine epidemic diarrhea (PED), and porcine reproductive and respiratory syndrome (PRRS) in farms worldwide have led to an increase in early vaccination of piglets. Other important drivers are the increasing number of awareness programs about porcine diseases and increased government funding for animal health care.

Technological advancements and growing research and development are expected to provide new profitable opportunities leading to the growth of the Global Porcine Vaccine Market. Combined vaccine production gives a good opportunity for growth. Also, DNA vaccines allow agriculture farmers to produce disease-free swine on their farms. Thus, there are ample growth opportunities for the market. However, there are some restraints like the high cost of maintaining, transportation, and storage of vaccines that are expected to adversely impact the growth of the Porcine Vaccine industry.

Global Porcine Vaccine Market Segmentation Analysis

The Global Porcine Vaccine Market is segmented on the basis of Disease Indication, Technology, And Geography.

Porcine Vaccine Market, By Disease Indication

• Swine Influenza
• Diarrhea
• Arthritis
• Porcine Reproductive and Respiratory Syndrome
• Porcine Circovirus Associated Disease
• Others

Based on Disease Indication, The market is segmented into Swine Influenza, Diarrhea, Arthritis, Porcine Reproductive and Respiratory Syndrome, Porcine Circovirus Associated Disease, and Others. Diarrhea and swine influenza dominate the Global Porcine Vaccine Market owing to factors like changes in climate including global warming and overfeeding of protein diet among others.

Porcine Vaccine Market, By Technology

• Inactivated vaccines
• Live attenuated vaccines
• Recombinant vaccines
• DNA vaccines
• Others

Based on Technology, The market is segmented into Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines, DNA vaccines, and Others. Inactivated vaccines are leading the market. DNA vaccines are gaining popularity in veterinary hospitals as they have several advantages over live attenuated vaccines and inactivated vaccines.

Porcine Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Porcine Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America leads the Global Porcine Vaccine Market by geography due to the rise in pork consumption, increasing instances of various swine diseases, and higher per-capita animal healthcare expenditure in the United States. The Asia Pacific region will have good growth due to increasing awareness about porcine health, and growing advancements in the field of biotechnology.

Key Players

The "Global Porcine Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bayer AG, Hipra, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A, Zoetis Inc., Arko Laboratories Ltd, and Vetoquinol. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• On August 5, 2021 Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-based biopharmaceutical company that specializes in novel detection technology to unlock high-volume, uncontrolled traditional therapies with specific therapies. The Vividion platform is capable of producing a wide range of therapeutic approaches to small molecules in all directions, with an initial focus on oncology and immunology. Vividion's leading programs include a wide range of oncology specification and immunology guidelines, with ongoing efforts to counteract NRF2 antagonism for the possible treatment of NRF2 cancer, and NRF2 activists for various inflammatory diseases such as acute intestinal disease - among other treatment programs.
• On February 18, 2021 Philippe Mauguin, INRAE chief executive officer and Drs. Marc Prikazsky, Chairman and CEO of Ceva Sante Animale (Ceva), signed a first-round agreement aimed at consolidating their animal health partnerships. This signature comes in the context of Covid-19 disease and the outbreak of bird flu in France. It affirms the shared goal of working together for the "One Health", global health concept at animal crossroads, human and environmental health and, in particular, to prevent infectious diseases from the environment and to improve animal welfare.